Showing results (81-90 of 242) with videos related to
Sort By:
Pageof 25
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 7, 2016
Helplessness/hopelessness, minimization and optimism predict survival in women with invasive ovarian cancer: a role for targeted support during initial treatment decision-making?Melanie A Price, Phyllis N Butow, Melanie L Bell, et al.Journal of Geriatric Oncology|May 27, 2019
Efficacy of immune checkpoint inhibitors in older adults with advanced stage cancers: A meta-analysisLawrence Kasherman, Derrick Ho Wai Siu, Kirsty Wai Chung Lee, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 24, 2022
Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patientsTharani Sivakumaran, Michael Krasovitsky, Alison Freimund, et al.Pathology|May 10, 2006
Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomasMorteza Aghmesheh, Zhenhe Suo, Michael Friedlander, et al.JCO Clinical Cancer Informatics|July 10, 2026
Enhancing Outcome Measurement in Oncology Clinical Trials Through Artificial Intelligence: A Scoping ReviewRachel Woodford, Sally Lord, Frank Lin, et al.Gynecologic Oncology|March 26, 2005
Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomasMorteza Aghmesheh, Lyndal Edwards, Christine L Clarke, et al.Gynecologic Oncology|December 8, 2004
No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancersMorteza Aghmesheh, Jahn M Nesland, Janne Kaern, et al.Journal of Cancer Survivorship : Research and Practice|February 28, 2021
The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivorsHannah C Timmins, Tiffany Li, David Goldstein, et al.Gynecologic Oncology|June 30, 2010
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancerMichael Friedlander, Kenneth C Hancock, Danny Rischin, et al.Cancer|January 5, 2022
The validity of progression-free survival 2 as a surrogate trial end point for overall survivalRachel G Woodford, Deborah D-X Zhou, Peey-Sei Kok, et al.Pageof 25